Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Check out my free class: The 3-Step Method to Prevent Kidney Stones Happy Eating
Alexander Kokkinos Carel Le Roux To view or add a comment, sign in Tirzepatide: Redefining Outcomes in Diabetes & Obesity Care Clinical trials show tirzepatide, a dual GIP/GLP-1 receptor agonist, is delivering results beyond expectations: Up to 20.9% mean weight loss at 72 weeks (SURMOUNT-1, NEJM) 94% risk reduction in progression from prediabetes to type 2 diabetes over 3 years Superior HbA1c reduction and weight control vs leading GLP-1 therapies (SURPASS program) With manageable side effects and durable outcomes, tirzepatide is reshaping how we approach metabolic disease
Cardiol Res Pract 2021:111
GI side effects are common to both compounds but may be more pronounced with retatrutide
Interactions between genetic variants and environmental factors affect risk of esophageal adenocarcinoma and Barretts esophagus
Meanwhile, 30% of functional dyspepsia patients have slow gastric emptying [5]
US$ 21.21
US$ 29.36
US$ 24.43
